The Learning Disabilities Network (LeaDNet): Using neurofibromatosis type 1 (NF1) as a paradigm for translational research

American Journal of Medical Genetics, Part A

Volumn 158 A, Issue 9, 2012, Pages 2225-2232

  Acosta, Maria T ^a,b   Bearden, Carrie E ^c   Castellanos, Xavier F ^d   Cutting, Laurie ^e   Elgersma, Ype ^f   Gioia, Gerard ^a   Gutmann, David H ^g   Lee, Yong Seok ^h   Legius, Eric ⁱ   Muenke, Maximillian ^b   North, Kathryn ⁱ   Parada, Luis F ^j   Ratner, Nancy ^k   Hunter Schaedle, Kim ^l   Silva, Alcino J ^c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^l Children's Tumor Foundation   (United States)

more..

Author keywords

Learning disabilities; Learning Disabilities Network; Neurodevelopmental disorders; Neurofibromatosis type 1; RAS MAPK pathway

Indexed keywords

MEVINOLIN; NEUROFIBROMIN; PLACEBO; RAS PROTEIN; SIMVASTATIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CANCER SUSCEPTIBILITY; COGNITIVE DEFECT; CONSENSUS DEVELOPMENT; DRUG PENETRATION; DYSLEXIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEALTH CARE ORGANIZATION; HUMAN; LEARNING DISABILITIES NETWORK; LEARNING DISORDER; LONG TERM POTENTIATION; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MORBIDITY; NEUROFIBROMATOSIS; NF1 GENE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT DURATION;

ANIMALS; HUMANS; LEARNING DISORDERS; MICE; NEUROFIBROMATOSIS 1; TRANSLATIONAL MEDICAL RESEARCH;

ANIMALIA;

EID: 84865562158     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.35535     Document Type: Review

References (57)

1. Acosta MT, Arcos-Burgos M, Muenke M. 2004. Attention deficit/hyperactivity disorder (ADHD): Complex phenotype, simple genotype? Genet Med 6:1-15.
2. Acosta MT, Gioia GA, Silva AJ. 2006. Neurofibromatosis type 1: New insights into neurocognitive issues. Curr Neurol Neurosci Rep 6:136-143.
3. Acosta MT, Castellanos FX, Bolton KL, Balog JZ, Eagen P, Nee L, Jones J, Palacio L, Sarampote C, Russell HF, Berg K, Arcos-Burgos M, Muenke M. 2008. Latent class subtyping of attention-deficit/hyperactivity disorder and comorbid conditions. J Am Acad Child Adolesc Psychiatry 47:797-807.
4. Acosta MT, Kardel PG, Walsh KS, Rosenbaum KN, Gioia GA, Packer RJ. 2011a. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: Phase I study. Pediatr Neurol 45:241-245.
5. Acosta MT, Velez JI, Bustamante ML, Arcos-Burgos M, Muenke M. 2011b. A two-locus genetic interaction between LPHN3 and 11 q predicts ADHD severity and long-term outcome. Transl Psychiatry 1:e17. DOI: 10.1038.14 Published online 5 July 2011.
6. Arcos-Burgos M, Castellanos FX, Pineda D, Lopera F, Palacio JD, Palacio LG, Rapoport JL, Berg K, Bailey-Wilson JE, Muenke M. 2004. Attention-deficit/hyperactivity disorder in a population isolate: Linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am J Hum Genet 75:998-1014.
7. Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D, Domene S, Velez JI, Karkera JD, Balog J, Berg K, Kleta R, Gahl WA, Roessler E, Long R, Lie J, Pineda D, Londono AC, Palacio JD, Arbelaez A, Lopera F, Elia J, Hakonarson H, Johansson S, Knappskog PM, Haavik J, Ribases M, Cormand B, Bayes M, Casas M, Ramos-Quiroga JA, Hervas A, Maher BS, Faraone SV, Seitz C, Freitag CM, Palmason H, Meyer J, Romanos M, Walitza S, Hemminger U, Warnke A, Romanos J, Renner T, Jacob C, Lesch KP, Swanson J, Vortmeyer A, Bailey-Wilson JE, Castellanos FX, Muenke M. 2010. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry 15:1053-1066.
8. Auerbach BD, Osterweil EK, Bear MF. 2011. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68.
9. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH. 2003. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63:8573-8577.
10. Barton B, North K. 2004. Social skills of children with neurofibromatosis type 1. Dev Med Child Neurol 46:553-563.
11. Brown JA, Emnett RJ, White CR, Yuede CM, Conyers SB, O'Malley KL, Wozniak DF, Gutmann DH. 2010a. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet 19:4515-4528.
12. Brown JA, Gianino SM, Gutmann DH. 2010b. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci 30:5579-5589.
13. Brown JA, Xu J, Diggs-Andrews KA, Wozniak DF, Mach RH, Gutmann DH. 2011. PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp Neurol 232:333-338.
14. Brown JA, Diggs-Andrews KA, Gianino SM, Gutmann DH. 2012. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. Mol Cell Neurosci 49:13-22.
15. Chabernaud C, Mennes M, Kardel PG, Gaillard WD, Kalbfleisch ML, VanMeter JW, Packer RJ, Milham MP, Castellanos FX, Acosta MT. 2012. Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1. Neurosci Lett 515:28-33.
16. Costa RM, Yang T, Huynh DP, Pulst SM, Viskochil DH, Silva AJ, Brannan CI. 2001. Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat Genet 27:399-405.
17. Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. 2002. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415:526-530.
18. Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ. 2008. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:549-560.
19. Cutting LE, Levine TM. 2010. Cognitive profile of children with neurofibromatosis and reading disabilities. Child Neuropsychol 16:417-432.
20. Dasgupta B, Dugan LL, Gutmann DH. 2003. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 23:8949-8954.
21. Denayer E, Ahmed T, Brems H, Van WG, Borgesius NZ, Callaerts-Vegh Z, Yoshimura A, Hartmann D, Elgersma Y, D'Hooge R, Legius E, Balschun D. 2008. Spred1 is required for synaptic plasticity and hippocampus-dependent learning. J Neurosci 28:14443-14449.
22. Descheemaeker MJ, Roelandts K, De RT, Brems H, Fryns JP, Legius E. 2004. Intelligence in individuals with a neurofibromatosis type 1 microdeletion. Am J Med Genet Part A 131A:325-326.
23. Edison RJ, Muenke M. 2004. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 350:1579-1582.
24. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. 2008a. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 14:843-848.
25. Ehninger D, Li W, Fox K, Stryker MP, Silva AJ. 2008b. Reversing neurodevelopmental disorders in adults. Neuron 60:950-960.
26. Ehninger D, Sano Y, de Vries PJ, Dies K, Franz D, Geschwind DH, Kaur M, Lee YS, Li W, Lowe JK, Nakagawa JA, Sahin M, Smith K, Whittemore V, Silva AJ. 2012. Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice. Mol Psychiatry 17:62-70.
27. Guo HF, Tong J, Hannan F, Luo L, Zhong Y. 2000. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 403:895-898.
28. Gutmann DH, Geist RT, Rose K, Wright DE. 1995. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev Dyn 202:302-311.
29. Gutmann DH, Zhang Y, Hirbe A. 1999. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Ann Neurol 46:777-782.
30. Ho IS, Hannan F, Guo HF, Hakker I, Zhong Y. 2007. Distinct functional domains of neurofibromatosis type 1 regulate immediate versus long-term memory formation. J Neurosci 27:6852-6857.
31. Hoeffer CA, Klann E. 2010. mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 33:67-75.
32. Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044.
33. Hyman SL, Arthur SE, North KN. 2006. Learning disabilities in children with neurofibromatosis type 1: Subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 48:973-977.
34. Hyman SL, Gill DS, Shores EA, Steinberg A, North KN. 2007. T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry 78:1088-1091.
35. Jain M, Velez JI, Acosta MT, Palacio LG, Balog J, Roessler E, Pineda D, Londono AC, Palacio JD, Arbelaez A, Lopera F, Elia J, Hakonarson H, Seitz C, Freitag CM, Palmason H, Meyer J, Romanos M, Walitza S, Hemminger U, Warnke A, Romanos J, Renner T, Jacob C, Lesch KP, Swanson J, Castellanos FX, Bailey-Wilson JE, Arcos-Burgos M, Muenke M. 2011. A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD. Mol Psychiatry 1-7 [Epub ahead of print].
36. Johnson CY, Rasmussen SA. 2010. Non-genetic risk factors for holoprosencephaly. Am J Med Genet Part C 154C:73-85.
37. Krab LC, Aarsen FK, de Goede-Bolder A, Catsman-Berrevoets CE, Arts WF, Moll HA, Elgersma Y. 2008a. Impact of neurofibromatosis type 1 on school performance. J Child Neurol 23:1002-1010.
38. Krab LC, de Goede-Bolder A, Aarsen FK, Pluijm SM, Bouman MJ, van der Geest JN, Lequin M, Catsman CE, Arts WF, Kushner SA, Silva AJ, De Zeeuw CI, Moll HA, Elgersma Y. 2008b. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial. JAMA 300:287-294.
39. Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF. 2006. Pten regulates neuronal arborization and social interaction in mice. Neuron 50:377-388.
40. Lee YS, Silva AJ. 2009. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci 10:126-140.
41. Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ. 2005. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961-1967.
42. Li Y, Li Y, McKay RM, Riethmacher D, Parada LF. 2012. Neurofibromin modulates adult hippocampal neurogenesis and behavioral effects of antidepressants. J Neurosci 32:3529-3539.
43. Listernick R, Louis DN, Packer RJ, Gutmann DH. 1997. Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143-149.
44. Lorenzo J, Barton B, Acosta MT, North K. 2011. Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr 158:660-665.
45. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, Dafre AL, Di GG, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB. 2007. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: Relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 27:5394-5404.
46. Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim C, McDonald M, Narayanan V, Pearn A, Pedersen R, Powell B, Shapiro LR, Skidmore D, Tegay D, Thiese H, Zackai EH, Vijzelaar R, Taniguchi K, Ayada T, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E. 2009. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 302:2111-2118.
47. Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN. 2010. Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol 25:834-841.
48. Raichle ME. 2010. Two views of brain function. Trends Cogn Sci 14:180-190.
49. Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T. 2010. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet Part A 152A:4-24.
50. Roessler E, Muenke M. 2010. The molecular genetics of holoprosencephaly. Am J Med Genet Part C 154C:52-61.
51. Shilyansky C, Karlsgodt KH, Cummings DM, Sidiropoulou K, Hardt M, James AS, Ehninger D, Bearden CE, Poirazi P, Jentsch JD, Cannon TD, Levine MS, Silva AJ. 2010. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci USA 107:13141-13146.
52. Silva AJ, Frankland PW, Marowitz Z, Friedman E, Laszlo GS, Cioffi D, Jacks T, Bourtchuladze R. 1997. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 15:281-284.
53. Solomon BD, Lange E, Shubrook J, Service FJ, Herman G, Karne RJ, Gorden P, Muenke M, Stratakis CA. 2010. Deletion of 8q24 in an adult with mild dysmorphic features, developmental delay, and ketotic hypoglycemia. Am J Med Genet Part A 152A:1545-1549.
54. Williams JA, Su HS, Bernards A, Field J, Sehgal A. 2001. A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK. Science 293:2251-2256.
55. Zhao Y, Fung C, Shin D, Shin BC, Thamotharan S, Sankar R, Ehninger D, Silva A, Devaskar SU. 2010. Neuronal glucose transporter isoform 3 deficient mice demonstrate features of autism spectrum disorders. Mol Psychiatry 15:286-299.
56. Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C, Powell CM, Parada LF. 2009. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci 29:1773-1783.
57. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF. 2005. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 132:5577-5588.